StockData
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. (IDYA) company profile

IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/307% below fair value
$27.40−2.96 (-9.75%)

Close on Nov 17, 2026Market cap $2.64BP/E –Yield –

About IDEAYA Biosciences

Pharmaceutical Preparations, SIC 2834

IDEAYA Biosciences, Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for cancer patients. The company focuses on developing synthetic lethality therapies and antibody-drug conjugates directed at molecularly defined solid tumors. Its clinical pipeline includes darovasertib, a protein kinase C inhibitor evaluated for the treatment of uveal melanoma, as well as investigational programs targeting the MTAP pathway and DNA damage response mechanisms. IDEAYA evaluates its drug candidates as monotherapies and in rational combinations for patients with specific genetic alterations, while collaborating with pharmaceutical partners to advance clinical development.

The company conducts clinical development activities primarily in the United States and collaborates globally with international pharmaceutical organizations. Its principal executive offices and headquarters are located in South San Francisco, California, and it maintains additional leased facilities in San Diego, California.

Summary of the business section of IDEAYA Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
IDEAYA Biosciences, Inc.
Founded
2015
Headquarters
South San Francisco, CA
Address
5000 Shoreline Ct, Suite 300 94080
Phone
(650) 443-6209
Employees
145, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
IDYA
Exchange
Nasdaq
IPO date
May 24, 2019
Shares outstanding
96M, Jul 31, 2026
Public float
$1.80B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1676725
CUSIP
45166A102
ISIN
US45166A1025
FIGI
BBG00CTZ4D83
Share class FIGI
BBG00CTZ4D92
LEI
549300ULW08F62IJML11
EIN
47-4268251

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yujiro S. HataPresident and CEO, Director690,695
Briseno Andres RuizChief Accounting Officer36,016
Theodora RossChief Development Officer–
Joshua BleharskiChief Financial Officer–
Michael Anthony WhiteChief Scientific Officer0
Darrin BeaupreChief Medical Officer–
Douglas B. SnyderSVP, General Counsel2,080
Stuart DormanChief Commercial Officer–
Wendy L. YarnoDirector–
Catherine J. MackeyDirector–
Scott W. MorrisonDirector–
Malcolm Garret HamptonDirector–
Terry J. RosenDirector16,346
Jeffrey SteinDirector57,644

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.51M$15.70M$2.72M$247$125
FY2024$16.93M$5.81M$4.54M$184$93
FY2023$6.00M$15.72M$2.02M$254$94
FY2022$3.33M$1.79M$2.01M$130$90
FY2021$3.85M$7.28M$2.47M$169$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Yujiro S. Hata
President and Chief Executive Officer
$700.00K–$8.42M$378.00K$15.80K$9.51M-44%
Joshua Bleharski
Chief Financial Officer
$333.33K$150.00K$3.46M$186.00K$14.01K$4.15M–
Andres Ruiz Briseno
Chief Accounting Officer
$417.00K–$1.05M$168.00K$15.80K$1.65M-51%
Darrin M. Beaupre
Chief Medical Officer
$526.50K–$2.60M$196.00K$15.80K$3.33M-45%
Michael A. White
Chief Scientific Officer
$519.00K–$2.60M$193.50K$15.80K$3.32M-38%
Douglas B. Snyder
Chief Legal Officer
$440.00K–$463.04K$164.00K$64.52K$1.13M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 24, 2019
Offer price
$10.00
Securities offered
5,000,000
Gross proceeds
$50.00M
Exchange
Nasdaq
First trading day
May 23, 2019
First-day close
$11.19+11.9%
Lock-up ends (est.)
Nov 19, 2019

“The initial public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 145 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?